{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50","upperLimit":"1532","value":"632"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"All subjects who received at least one dose of temsirolimus at the MTD, 20 mg/M\\^2 plus liposomal doxorubicin were included.","id":"OG000","title":"Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2"}],"paramType":"MEAN","populationDescription":"Subjects who received Temsirolimus MTD, 20 mg/m\\^2 in Phase I of the study and all subjects in the Phase II study were included from both Phase I and Phase II of the study are included.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Mean Overall Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2","type":"SECONDARY","unitOfMeasure":"Days"}